Effects of Time from Diagnosis to Treatment and Baseline Vision on Retinal Vein Occlusion Outcomes in Aflibercept 2 mg Phase III Trials
Ophthalmology Retina · 2026
DOI: 10.1016/j.oret.2026.04.027 ↗Kurz gefasst
Klinische Studie (Phase III) in der Zeitschrift Ophthalmology Retina, 2026. Verfasst von Sumit Sharma und 7 weiteren Autor:innen. Beteiligte Einrichtung: Cole Eye Institute, Cleveland Clinic, Cleveland, Ohio. Hauptthemen laut MEDLINE: Recombinant Fusion Proteins, Receptors, Vascular Endothelial Growth Factor, Retinal Vein Occlusion, Visual Acuity. Die Arbeit nennt 18 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Regeneron Pharmaceuticals Inc.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Cole Eye Institute, Cleveland Clinic, Cleveland, Ohio.
- California Retina Consultants/Retina Consultants of America, Santa Barbara, California.
- Duke Eye Center, Durham, North Carolina.
- Regeneron Pharmaceuticals, Inc, Tarrytown, New York.
- Retina Vitreous Associates Medical Group, Los Angeles, California. Electronic address: vitdoc@aol.com.
Förderung
- Regeneron Pharmaceuticals Inc
Zitieren
APA
Sharma, S., Dhoot, D. S., Grewal, D. S., Jung, E., Silva, F. Q., Du, W., Moini, H., & Boyer, D. S. (2026). Effects of Time from Diagnosis to Treatment and Baseline Vision on Retinal Vein Occlusion Outcomes in Aflibercept 2 mg Phase III Trials. Ophthalmology Retina. https://doi.org/10.1016/j.oret.2026.04.027
Vancouver
Sharma S, Dhoot DS, Grewal DS, Jung E, Silva FQ, Du W, et al. Effects of Time from Diagnosis to Treatment and Baseline Vision on Retinal Vein Occlusion Outcomes in Aflibercept 2 mg Phase III Trials. Ophthalmology Retina. 2026. doi:10.1016/j.oret.2026.04.027
BibTeX
@article{Sharma2026,
author = {Sharma, Sumit and Dhoot, Dilsher S and Grewal, Dilraj S and Jung, Eric and Silva, Fabiana Q and Du, Weiming and Moini, Hadi and Boyer, David S},
title = {Effects of Time from Diagnosis to Treatment and Baseline Vision on Retinal Vein Occlusion Outcomes in Aflibercept 2 mg Phase III Trials},
journal = {Ophthalmology Retina},
year = {2026},
doi = {10.1016/j.oret.2026.04.027}
}
EUVIMED